NEW
Stock Screener with Intrinsic Value
Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$409.9(0.5%)
Market Cap$105.0B
DCF value
$493.3
Undervalued (DCF value)
20.3%
Discount Rate
7.9%
Long-Term Growth Rate
3.0%
Stock quality
6/10
Good
VRTX DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
VRTX DCF Value
Crunching data... Almost there!
VRTX DCF Financials
Crunching data... Almost there!
VRTX DCF sensitivity
Crunching data... Almost there!
Explore more intrinsic value tools hub for VRTX
Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Vertex Pharmaceuticals Incorporated DCF (discounted cash flow) valuation?
As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at $493.3. This suggests it may be undervalued by 20.3% compared to its current price of around $409.9, using a WACC of 7.9% and growth rates of 3.0%.
What is Vertex Pharmaceuticals Incorporated WACC?
As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated's Weighted Average Cost of Capital (WACC) is approximately 7.9%.
What is Vertex Pharmaceuticals Incorporated Enterprise Value?
As of Jan 10, 2025, Vertex Pharmaceuticals Incorporated's Enterprise Value (EV) is approximately $115.9B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.